CLAIMS

1. A pharmaceutical composition including about 2.5 mg loratadine, or a corresponding amount in the form of a suitable salt thereof, together with a hydroxy-α-[(methylamino)methyl]-benzenemethanol, or a suitable salt thereof, for use in a method of treating upper respiratory/mucosal congestion by administering to a patient four times a day.

2. A composition according to claim 1 which is for administering on a qid basis.

3. A composition according to claim 1 or 2, where the hydroxy-α-[(methylamino) methyl]benzenemethanol is 3-hydroxy-α-[(methylamino) methyl]-benzenemethanol (phenylephrine).

4. A composition according to claim 1, 2 or 3, including about 8 to 10 mg of phenylephrine free base or a corresponding amount in the form of a suitable salt thereof.

5. A composition according to claim 3 or 4, where the phenylephrine is present as a hydrochloride salt.

6. A composition according to claim 5, including 10 to 12.2mg of the hydrochloride salt.

7. A composition according to any one of claims 1 to 6, which is in a solid dosage form.

8. The use of about 2.5 mg loratadine, together with a hydroxy-α-[(methylamino)methyl]-benzenemethanol, or a suitable salt thereof, in the manufacture of a medicament for the treatment of upper respiratory/mucosal congestion, wherein the medicament is for administration to a patient four times a day.

9. The use according to claim 8, comprising the use of 8 to 10 mg of phenylephrine, or a corresponding amount in the form of suitable salt thereof, in the manufacture of the medicament.

10. The use according to claim 9, where the medicament is manufactured for administration qid.

11. The use according to claim 9 or 10, where the phenylephrine is in a salt form.

12. The use according to claim 11, where the phenylephrine salt is the hydrochloride salt.

13. A pharmaceutical composition according to any one of the preceding claims where the pharmaceutical composition includes pharmaceutically acceptable non-active excipients and/or carriers.

14. A pharmaceutical composition according to any one of the preceding claims where the pharmaceutical composition is a pill, capsule or tablet.

15. A pharmaceutical composition according to any one of the preceding claims comprising 10.00 mg phenylephrine hydrochloride, 2.50 mg loratadine, 180.40 mg lactose, 140.00 mg maize starch, 10.365 mg pregelatinised starch, 0.20mg lake of quinoline yellow, 0.40mg sodium metabisulphite, 0.14mg disodium EDTA, 3.00 mg talc, and 3.00 mg magnesium stearate

16. A pack including pills, tablets or capsules in the form of a pharmaceutical composition according to any one of the preceding claims wherein the pack includes instructions to administer the composition a maximum of 4 times a day.

17. A container containing a syrup including loratadine and phenylephrine, or suitable salts thereof, at concentrations suitable for administration of about 2.5 mg loratadine and about 8 to 10 mg phenylephrine per unit dose, the container including instructions to administer an amount of syrup that will deliver about 2.5 mg loratadine and about 8 to 10 mg phenylephrine per unit dose 4 times a day.

18. A container according to claim 17 where the phenylephrine is in a salt form.

19. A container according to claim 18, where the phenylephrine is in the form of a hydrochloride salt.

20. A pharmaceutical composition including about 2.5 mg loratadine, or a corresponding amount in the form of a suitable salt thereof, as the only therapeutically active ingredient, for administering to a patient four times a day for treating upper respiratory/mucosal congestion.

**CLAIMS**

1. A pharmaceutical composition including about 2.5mg loratadine, or a corresponding amount in the form of a suitable salt thereof, together with about 8 to 10mg of 3-hydroxy-o-[(methylamino)methyl]benzenemethanol(phenylephrine) free base or a suitable salt thereof, for use in a method of treating upper respiratory/mucosal congestion by administering to a patient four times a day.

2. A composition according to claim 1, where the phenylephrine is present as a hydrochloride salt.

3. A composition according to claim 1, including 10 to 12.2mg of the hydrochloride salt.

4. A composition according to any one of the preceding claims, which is in a solid dosage form.

5. The use of about 2.5mg loratadine, together with about 8 to 10mg of 3-hydroxy-o-[(methyl- amino)methyl]benzenemethanol(phenylephrine) free base, or a suitable salt thereof, in the manufacture of a medicament for the treatment of upper respiratory/mucosal congestion, wherein the medicament is for administration to a patient four times a day.

6. The use according to claim 5, comprising the use of 8 to 10mg of phenylephrine, or a corresponding amount in the form of suitable salt thereof, in the manufacture of the medicament.

7. The use according to claim 6, where the medicament is manufactured for administration qid.

8. The use according to claim 6 or claim 7, where the phenylephrine is in a salt form.

9. The use according to claim 8, where the phenylephrine salt is the hydrochloride salt.

10. A pharmaceutical composition according to any one of the preceding claims, where the pharmaceutical composition includes pharmaceutically acceptable non-active excipients and/or carriers.

11. A pharmaceutical composition according to any one of the preceding claims, where the pharmaceutical composition is a pill, capsule or tablet.

12. A pharmaceutical composition according to any one of the preceding claims, comprising 10.00mg phenylephrine hydrochloride, 2.50mg loratadine, 180.40mg lactose, 140.00mg maize starch, 10.365mg pregelatinised starch, 0.20mg lake of quinoline yellow, 0.40mg sodium metabisulphite, 0.14mg disodium EDTA, 3.00mg talc, and 3.00mg magnesium stearate

13. A pack including pills, tablets or capsules in the form of a pharmaceutical composition according to any one of the preceding claims wherein the pack includes instructions to administer the composition a maximum of four times a day.

14. A container containing a syrup including loratadine and phenylephrine, or suitable salts thereof, at concentrations suitable for administration of about 2.5mg loratadine and about 8 to 10mg phenylephrine per unit dose, the container including instructions to administer an amount of syrup that will deliver about 2.5mg loratadine and about 8 to 10mg phenylephrine per unit dose four times a day.

15. A container according to claim 14, where the phenylephrine is in a salt form.

16. A container according to claim 15, where the phenylephrine is in the form of a hydrochloride salt.